Identification of Biomarkers to Stratify Response to B-Cell-Targeted Therapies in Systemic Lupus Erythematosus: An Exploratory Analysis of a Randomised Controlled Trial

The authors found a predictive association between baseline serum IgA2 anti-double stranded DNA antibody concentrations and clinical response to belimumab after rituximab, with a between-group difference in major clinical response of 48% (95% CI 10 to 70).